Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 265,159
  • Shares Outstanding, K 98,940
  • Annual Sales, $ 16,490 K
  • Annual Income, $ -60,410 K
  • EBIT $ -58 M
  • EBITDA $ -56 M
  • 60-Month Beta 1.26
  • Price/Sales 16.09
  • Price/Cash Flow N/A
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 196.09% ( +0.77%)
  • Historical Volatility 59.10%
  • IV Percentile 93%
  • IV Rank 51.14%
  • IV High 357.22% on 04/19/24
  • IV Low 27.45% on 08/05/24
  • Put/Call Vol Ratio 5.78
  • Today's Volume 61
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 1,402
  • Open Int (30-Day) 1,302

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 3
  • High Estimate -0.20
  • Low Estimate -0.23
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -266.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +2.29%
on 12/19/24
3.48 -22.99%
on 11/25/24
-0.56 (-17.28%)
since 11/20/24
3-Month
2.62 +2.29%
on 12/19/24
3.98 -32.66%
on 09/23/24
-1.01 (-27.37%)
since 09/20/24
52-Week
2.25 +19.11%
on 04/26/24
5.14 -47.86%
on 12/28/23
-1.37 (-33.83%)
since 12/20/23

Most Recent Stories

More News
AC Immune Reports Positive Interim Safety Data for ACI-24.060 in Down Syndrome Phase 1b/2 ABATE Trial

AC Immune reports positive interim safety data for ACI-24.060 in Down syndrome, showing no serious adverse events noted.Quiver AI SummaryAC Immune SA announced positive interim safety data from its Phase...

ACIU : 2.68 (-0.74%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.68 (-0.74%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 2.68 (-0.74%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 2.68 (-0.74%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.68 (-0.74%)
AC Immune: Q2 Earnings Snapshot

AC Immune: Q2 Earnings Snapshot

ACIU : 2.68 (-0.74%)
Why Shares of AC Immune Jumped This Week

The FDA has granted a Fast Track Designation to its Alzheimer's disease vaccine candidate.

ACIU : 2.68 (-0.74%)
AC Immune: Q1 Earnings Snapshot

AC Immune: Q1 Earnings Snapshot

ACIU : 2.68 (-0.74%)
Is Ardelyx is A Buy After Slip in Early 2022

Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them

ARDX : 4.82 (+2.77%)
CNCE : 8.37 (+0.12%)
KYKOF : 14.9700 (-6.73%)
SFOSF : 1.7800 (unch)
KHTRF : 3.6200 (+0.84%)
ACIU : 2.68 (-0.74%)
BMEA : 4.23 (+3.68%)
AC Immune: Q3 Earnings Snapshot

AC Immune: Q3 Earnings Snapshot

ACIU : 2.68 (-0.74%)

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

3rd Resistance Point 2.90
2nd Resistance Point 2.84
1st Resistance Point 2.76
Last Price 2.68
1st Support Level 2.62
2nd Support Level 2.55
3rd Support Level 2.47

See More

52-Week High 5.14
Fibonacci 61.8% 4.04
Fibonacci 50% 3.69
Fibonacci 38.2% 3.35
Last Price 2.68
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar